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Neoadjuvant chemotherapy in breast cancer: more than just 
downsizing 
The Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) has established a new milestone in evidence-
based treatment for early breast cancer. Through 
longstanding collaboration, mutual trust, and data 
transparency, they have gathered individual patient 
data for 4756 women randomly allocated in ten trials to 
either neoadjuvant chemotherapy (NACT) or adjuvant 
chemotherapy, with a median follow-up of 9 years 
(IQR 5–14). The results of this meta-analysis,1 published 
in The Lancet Oncology, substantiate that NACT 
results in higher rates of breast-conserving therapy 
than does adjuvant chemotherapy (rate ratio 1·28 
[95% CI 1·22–1·34]), without compromising on distant 
recurrence, breast cancer survival, or overall survival.  
Much emphasis is given by the authors to an increase 
in local recurrence in the NACT group (15 year absolute 
increase of 5·5% [95% CI 2·4–8·6]). Whether NACT itself 
could be held accountable for the small increase in local 
recurrences is questionable. Higher local recurrence 
with breast-conserving surgery than with mastectomy 
is inherent to breast-conserving therapy. The meta-
analysis by Mieog and colleagues2 showed no significant 
difference in local recurrence between patients receiving 
breast-conserving surgery after NACT and breast-
conserving surgery followed by adjuvant chemotherapy, 
even with inclusion of those receiving NACT that were 
initially scheduled for mastectomy.
In the meta-analysis by the EBCTCG,1 NACT led to 
response of the primary tumour, which undoubtedly 
led to concomitant downstaging of the axillary lymph 
nodes. Unfortunately, the EBCTCG was not able to 
collect data for lymph node status before and after 
neoadjuvant treatment in these trials. Moreover, axillary 
treatment strategies have drastically changed in the last 
two decades, making interpretation of older findings 
difficult. Probably for these reasons, downstaging of 
lymph node status was not discussed in the Article. 
Axillary lymph node dissection is associated with 
substantial long-term morbidity and is often considered 
to be worse than morbidity caused by breast surgery. 
Studies3,4 have shown that pathological complete 
response (pCR) of the axilla is achieved in 41–75% of 
patients with HER2-positive or triple-negative cancer 
receiving NACT. Especially among patients with an 
ultrasound-positive or cytological-positive axilla who 
had a clinical response with downstaging to a negative 
axilla, controversy still exists regarding the timing and 
accuracy of nodal staging with sentinel lymph node 
biopsy.5,6 Several studies have addressed the accuracy 
of nodal staging after NACT and current consensus is 
that sentinel lymph node biopsy after NACT in patients 
with initial positive axilla is considered accurate if at 
least three or more sentinel nodes are detected and 
examined.6 Although the willingness of surgeons to 
omit axillary lymph node dissection or radiotherapy of 
the axilla in patients with complete response to NACT 
is high,7 no studies have yet investigated locoregional 
outcomes. A randomised phase 3 trial8 is ongoing 
to assess the role of axillary radiotherapy versus no 
axillary radiotherapy in patients who converted to 
pathologically node-negative disease after NACT. 
As was shown in the EBCTCG meta-analysis, patients 
with high-grade, hormone receptor-negative tumours 
were most likely to achieve a complete clinical 
response of the primary tumour after NACT. With 
the introduction of targeted therapies and improved 
systemic strategies, substantial improvements in 
pCR have been seen in the past decade, especially in 
patients with HER2-positive or triple-negative breast 
cancers. Several trials have reported consistently 
high pCR proportions of up to 83% among HER2-
positive, hormone receptor-negative cancers treated 
preoperatively with combination chemotherapy and 
(dual) targeted anti-HER2 agents.9 These complete 
responders are offered routine breast cancer surgery 
similar to patients who did not receive NACT. 
A consensus statement6 on the extent of breast 
cancer surgery after NACT recommends inclusion 
of only the radiological residual area of the primary 
tumour. When this recommendation is extrapolated 
to patients with a radiological complete response, 
the question is raised as to whether breast surgery 
could be considered an unnecessary procedure. 
Safe omission of surgery depends on the ability to 
identify pCR preoperatively. Obviously, the tumour 
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The immune microenvironment is now recognised 
as crucial in the treatment of cancer. The tumour 
immune infiltrate has been noted to be associated 
with better outcomes in HER2-positive breast cancer 
and triple-negative breast cancer (TNBC), in both 
the early-stage and the advanced disease setting.1,2 
Incorporating the quantity of the pre-existing immune 
response with other prognostic clinical pathological 
factors, such as tumour size and nodal status, will allow 
clinicians to better estimate long-term survival after 
breast cancer diagnosis.3 Such data will help clinicians 
improve their treatment recommendations and allow 
us to design clinical trials of novel treatments for the 
subgroups that need the most improvement in survival.
In The Lancet Oncology, Carsten Denkert and colleagues4 
have assessed the predictive and prognostic effect of 
the concentration of tumour-infiltrating lymphocytes 
(TILs), assessed by use of pretreatment haematoxylin 
and eosin (H&E) stained slides of core biopsies, from 
patients enrolled in six randomised trials investigating 
neo-adjuvant treatment in breast cancer.4 3771 patient 
samples were assessed, which constituted the largest 
pooled analysis on the effect of TILs in the neoadjuvant 
setting to date. The authors confirmed the importance 
of TIL quantity in the prediction of pathological complete 
response, independent of breast cancer subtype, and 
pathological complete response was strongly associated 
with a better prognosis (disease free-survival) in patients 
with TNBC and HER2-positive breast cancer, but not in a 
small luminal–HER2-negative subgroup. 
The finding in luminal cancers raises questions on 
the relevance of T cells in the biology of these cancers. 
of NACT to localise the residual tumour after NACT. 
Several groups are investigating the accuracy of 
core needle biopsies in the marked area to establish 
pCR after neoadjuvant treatment, in either those 
with radiological complete response (MICRA study; 
TrialRegister.nl, number NTR6120) or those with 
HER2-positive or triple-negative disease with partial 
or complete response (NCT02455791). On the basis 
of initial findings of high accuracy of core needle 
biopsies in small studies, single-arm studies have 
started recruitment to establish long-term outcomes 
for omission of breast surgery (NCT02945579).9,10
With the evidence generated from this meta-analysis, 
patients with large tumours can be recommended to 
have NACT and subsequent breast-conserving surgery 
depending on response assessment. Further studies 
will tailor the optimum extent of breast and axillary 
treatment on the basis of response to NACT. 
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